Literature DB >> 10023903

HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy.

V Natarajan, M Bosche, J A Metcalf, D J Ward, H C Lane, J A Kovacs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10023903     DOI： 10.1016/s0140-6736(05)76156-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  47 in total

1.  Effects of therapy with highly active anti-retroviral therapy (HAART) and IL-2 on CD4+ and CD8+ lymphocyte apoptosis in HIV+ patients.

Authors:  L Caggiari; S Zanussi; M T Bortolin; M D'andrea; G Nasti; C Simonelli; U Tirelli; P De Paoli
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

2.  Benchmarks for antiretroviral therapy.

Authors:  O J Cohen; A S Fauci
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

3.  Reservoirs for HIV-1.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

4.  HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir.

Authors:  Tae-Wook Chun; David C Nickle; J Shawn Justement; Danielle Large; Alice Semerjian; Marcel E Curlin; M Angeline O'Shea; Claire W Hallahan; Marybeth Daucher; Douglas J Ward; Susan Moir; James I Mullins; Colin Kovacs; Anthony S Fauci
Journal:  J Clin Invest       Date:  2005-11       Impact factor: 14.808

5.  Antiretroviral Drug Concentrations in Lymph Nodes: A Cross-Species Comparison of the Effect of Drug Transporter Expression, Viral Infection, and Sex in Humanized Mice, Nonhuman Primates, and Humans.

Authors:  Erin Burgunder; John K Fallon; Nicole White; Amanda P Schauer; Craig Sykes; Leila Remling-Mulder; Martina Kovarova; Lourdes Adamson; Paul Luciw; J Victor Garcia; Ramesh Akkina; Philip C Smith; Angela D M Kashuba
Journal:  J Pharmacol Exp Ther       Date:  2019-06-24       Impact factor: 4.030

6.  Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy.

Authors:  Tuofu Zhu; David Muthui; Sarah Holte; David Nickle; Feng Feng; Scott Brodie; Yon Hwangbo; James I Mullins; Lawrence Corey
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

7.  Nine crystal structures determine the substrate envelope of the MDR HIV-1 protease.

Authors:  Zhigang Liu; Yong Wang; Joseph Brunzelle; Iulia A Kovari; Ladislau C Kovari
Journal:  Protein J       Date:  2011-03       Impact factor: 2.371

Review 8.  Overcoming pharmacologic sanctuaries.

Authors:  Theodore J Cory; Timothy W Schacker; Mario Stevenson; Courtney V Fletcher
Journal:  Curr Opin HIV AIDS       Date:  2013-05       Impact factor: 4.283

9.  Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells.

Authors:  Antonio Valentin; Matthew Morrow; Richard H Poirier; Karen Aleman; Richard Little; Robert Yarchoan; George N Pavlakis
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

10.  HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.

Authors:  Maud Mavigner; Pierre Delobel; Michelle Cazabat; Martine Dubois; Fatima-Ezzahra L'faqihi-Olive; Stéphanie Raymond; Christophe Pasquier; Bruno Marchou; Patrice Massip; Jacques Izopet
Journal:  PLoS One       Date:  2009-10-30       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.